Subject: NIH GUIDE - V20(26) 07/05/91
From: Dot Baker <[email-masked]>
To: [email-masked]
Date: Fri, 05 Jul 91 08:42 EST

Hi Paul:
The current NIH Guide has arrived.  It will be forwarded in 2 parts.
Please post this one to the NIH Listserver as:
NIHGUIDE.910705.
             Thanks, Mary Broaddus
 
NIH GUIDE - Vol. 20, No. 26, July 5, 1991
 
$$INDEX BEGIN **********************************************************
 
                                   NOTICES
 
$$INDEX N1 *************************************************************
 
ELIGIBILITY REQUIREMENTS FOR FOGARTY INTERNATIONAL CENTER FELLOWSHIPS
Fogarty International Center
Index:  FOGARTY INTERNATIONAL CENTER
 
$$INDEX N2 *************************************************************
 
DISCONTINUATION OF THE SPONSOR'S SALARY ON PHYSICIAN SCIENTIST AWARDS
AND PHYSICIAN SCIENTIST PROGRAM AWARDS
National Institutes of Health
Index:  NATIONAL INSTITUTES OF HEALTH

                   NOTICES OF AVAILABILITY (RFPs AND RFAs)
 
$$INDEX R1 *************************************************************
 
STUDIES TO EVALUATE THE TOXIC AND CARCINOGENIC POTENTIAL OF 60 Hz
MAGNETIC FIELDS IN LABORATORY ANIMALS (RFP)
National Institute of Environmental Health Sciences
Index:  ENVIRONMENTAL HEALTH SCIENCES
 
$$INDEX R2 *************************************************************
 
FAMILY AND GENETICS STUDIES OF CARDIOVASCULAR DISEASE - FIELD
CENTERS (RFP)
National Heart, Lung, and Blood Institute
Index:  HEART, LUNG, BLOOD
 
$$INDEX R3 *************************************************************
 
FAMILY AND GENETICS STUDIES OF CARDIOVASCULAR DISEASE - BLOOD
LABORATORY (RFP)
National Heart, Lung, and Blood Institute
Index:  HEART, LUNG, BLOOD
 
$$INDEX R4 *************************************************************
 
SPEECH PROCESSORS FOR AUDITORY PROSTHESES (RFP)
National Institute on Deafness and Other Communication Disorders
Index:  DEAFNESS, COMMUNICATION DISORDERS
 
$$INDEX R5 03/18/92 ****************************************************
 
STRUCTURAL BIOLOGY AS APPLIED TO THE PROBLEM OF TARGETED DRUG DESIGN,
WITH POTENTIAL APPLICABILITY TO THE TREATMENT OF AIDS (RFA GM-91-02)
National Institute of General Medical Sciences
Index:  GENERAL MEDICAL SCIENCES

                        ONGOING PROGRAM ANNOUNCEMENTS
 
$$INDEX P1 *************************************************************
 
DRUG ABUSE PREVENTION RESEARCH GRANT ANNOUNCEMENT (PA-91-73)
National Institute on Drug Abuse
Index:  DRUG ABUSE
 
$$INDEX P2 *************************************************************
 
RESEARCH ON DISABILITIES AND REHABILITATION SERVICES FOR PERSONS WITH
SEVERE MENTAL DISORDERS (PA-91-74)
National Institute of Mental Health
Index:  MENTAL HEALTH

                                    ERRATA
 
$$INDEX E1 *************************************************************
 
ADULT AIDS CLINICAL TRIALS UNITS (RFA AI-91-07)
National Institute of Allergy and Infectious Diseases
Index:  ALLERGY, INFECTIOUS DISEASES
 
$$INDEX END ************************************************************

                                   NOTICES
 
$$N1 BEGIN *************************************************************
 
ELIGIBILITY REQUIREMENTS FOR FOGARTY INTERNATIONAL CENTER FELLOWSHIPS
 
P.T. 22; K.W. 0720005, 1014006
 
Fogarty International Center
 
The Fogarty International Center (FIC) announces a change in eligibility
requirements for all of the FIC-sponsored fellowship programs.  FIC, in
line with other NIH fellowship programs, now requires that all
fellowship recipients hold the doctoral level degree (e.g., Ph.D., M.D.,
D.D.S., D.V.M., and O.D.) prior to award of the fellowship that is
usually made within nine months of submission.  The previous requirement
stated that the degree must have been obtained prior to submission of
the fellowship application.  This notice applies to all applicants for
fellowships sponsored by the FIC and is effective as of the date of this
publication.
 
$$N1 END ***************************************************************
 
$$N2 BEGIN *************************************************************
 
DISCONTINUATION OF THE SPONSOR'S SALARY ON PHYSICIAN SCIENTIST AWARDS
AND PHYSICIAN SCIENTIST PROGRAM AWARDS
 
P.T. 34; K.W. 1014006
 
National Institutes of Health
 
The National Institutes of Health (NIH) will discontinue payment of the
sponsor's salary on competing Physician Scientist (K11) and Physician
Scientist Program (K12) awards beginning with awards from fiscal year
1992 funds.
 
Initial review groups will be advised to disregard requests for a
sponsor's salary in Physician Scientist Award applications submitted for
the February 1 and June 1, 1991 receipt dates.  Applications for
Physician Scientist Awards submitted for the October 1, 1991 and
subsequent receipt dates may not contain a request for the sponsor's
salary.
 
The NIH will continue to pay existing commitments regarding the
sponsor's salary on K11 and K12 awards made before fiscal year 1992.
 
$$N2 END ***************************************************************
 
                   NOTICES OF AVAILABILITY (RFPs AND RFAs)
 
$$R1 BEGIN NIH-ES-92-11 ************************************************
 
STUDIES TO EVALUATE THE TOXIC AND CARCINOGENIC POTENTIAL OF 60 Hz
MAGNETIC FIELDS IN LABORATORY ANIMALS
 
RFP AVAILABLE:  NIH-ES-92-11
 
P.T. 34; K.W. 1007009, 1013026, 0715035
 
National Institute of Environmental Health Sciences
 
The National Institute of Environmental Health Sciences (NIEHS),
National Institutes of Health (NIH), is soliciting proposals for studies
designed to characterize the toxicity and carcinogenicity of 60 Hz
sinusoidal magnetic fields in Fischer 344 rats and B6C3F1 mice, to
determine if such fields alter pineal function, and to determine if such
fields cause developmental or reproductive toxicity.  This project will
be separated into two phases.  Phase 1 will be a six-month period
comprised only of those work activities associated with procurement of
equipment and materials needed to construct the exposure and monitoring
systems, the construction/renovation of the exposure and monitoring
systems, and the developmental effort needed to determine that the
systems function appropriately and will meet the National Toxicology
Program specifications.  The government will evaluate the results of
Phase 1 and may exercise an option for Phase 2 requirements.  Phase 2
will be a four-year, six-month period involving the conduct of
eight-week and 104-week studies in which animals will be exposed to
magnetic fields of specified intensities using the exposure system
developed in Phase 1.  The Government estimates that Phase 1 will
require approximately .67 professional person-years of effort and .48
technical person-years of effort.  Phase 2 will require approximately
5.8 professional person-years of effort and 20.1 technical person-years
of effort.  All responsible sources may submit a proposal that shall be
considered by the Agency.
 
The Request for Proposals NIH-ES-92-11 will be issued on July 15.
Responses will be due by close of business September 13.  NIEHS plans to
make one award from this solicitation.
 
Requests for the Request for Proposals must reference RFP NIH-ES-92-11
and must be forwarded to:
 
National Institute of Environmental Health Sciences
Contracts and Procurement Management Branch, OM
ATTN:  Ms. Mary B. Armstead, Contracting Officer
79 T.W. Alexander Drive, 4401 Research Commons Building
P.O. Box 12874
Research Triangle Park, NC  27709
Telephone:  (919) 541-7893
 
$$R1 END ***************************************************************
 
$$R2 BEGIN NHLBI-HC-91-08 **********************************************
 
FAMILY AND GENETICS STUDIES OF CARDIOVASCULAR DISEASE - FIELD CENTERS
 
RFP AVAILABLE:  NHLBI-HC-91-08
 
P.T. 34; K.W. 0715035, 1002019, 0411005
 
National Heart, Lung, and Blood Institute
 
The National Heart, Lung, and Blood Institute (NHLBI) requires three to
five field centers to initiate a family and genetic study of
cardiovascular disease (CVD) within existing United States population
based epidemiological studies.  The centers will have a total of
approximately 6000 participants.  Centers in the areas of ultrasound,
electrocardiography, and pulmonary function are anticipated within the
field centers' solicitation.  The objective of the proposed contract is
to identify and evaluate genetic and nongenetic determinants of familial
aggregation of cardiovascular disease and risk factors.  The period of
performance is anticipated for four years beginning in January 1992.
 
This is an announcement of the availability of a Request for Proposals
(RFP).  RFP NHLBI-HC-91-08 will be available on or about July 8, 1991,
with proposals due September 9, 1991.  Three to five awards are
anticipated by the Government.  Offerors other than U.S. institutions
will not be considered.  Written requests for this RFP must include
three (3) mailing labels, self-addressed, and must cite RFP
NHLBI-HC-91-08.
 
Requests for copies of the RFP must be sent to:
 
Lisa O'Neill
Contracts Specialist for
ECA Contracts Section
National Heart, Lung, and Blood Institute
Federal Building, Room 200
Bethesda, MD  20892
 
$$R2 END ***************************************************************
 
$$R3 BEGIN NHLBI-HC-91-09 **********************************************
 
FAMILY AND GENETICS STUDIES OF CARDIOVASCULAR DISEASE - BLOOD LABORATORY
 
RFP AVAILABLE:  NHLBI-HC-91-09
 
P.T. 34; K.W. 0715035, 1002019, 0411005, 0750010
 
National Heart, Lung, and Blood Institute
 
The National Heart, Lung, and Blood Institute (NHLBI) requires a central
blood laboratory to perform tests and measurements on approximately 6000
participants involved in a family and genetic study of cardiovascular
disease (CVD) in existing United States population based epidemiological
studies.  The blood tests to be performed are:  cholesterol,
HDL-cholesterol, triglycerides, apolipoproteins phenotypes, Lp(a),
fibrinogen, factor VII activity, PAI-1, chemistries (urea, uric acid,
creatinine), homocysteine, insulin, glucose, renin, RBC, Li/Na
countertransport, and hematology.  The white cells and plasma are to be
stored for later molecular genetic studies.  The period of performance
is anticipated to be for three years, nine months beginning March 1992.
 
This is an announcement of the availability of a Request for Proposals
(RFP).  RFP NHLBI-HC-91-09 will be available on or about July 17, 1991,
with proposals due September 9, 1991.  One award is anticipated by the
Government.  Offerors other than U.S. institutions will not be
considered.  Written requests must include three (3) mailing labels,
self-addressed, and must cite RFP NHLBI-HC-91-09.
 
Requests for copies of the RFP must be sent to:
 
Lisa O'Neill
Contracts Specialist for
ECA Contracts Section
National Heart, Lung, and Blood Institute
Federal Building, Room 200
Bethesda, MD  20892
 
$$R3 END ***************************************************************
 
$$R4 BEGIN NIH-NIDCD-91-02 *********************************************
 
SPEECH PROCESSORS FOR AUDITORY PROSTHESES
 
RFP AVAILABLE:  NIH-NIDCD-91-02
 
P.T. 34; K.W. 0775005, 0740060, 0740030
 
National Institute on Deafness and Other Communication Disorders
 
The National Institute of Deafness and Other Communication Disorders
(NIDCD) has a requirement for the continued design, development, and
evaluation of speech processors for use with implanted auditory
prostheses in deaf humans.
 
The NIDCD supports research and development on auditory prostheses for
deaf individuals.  An essential component of all auditory prostheses is
the speech processor whose function is to convert the wideband
electrical signal from the microphone to an information condensed signal
or set of signals for driving the individual electrical implant
stimulators in a manner to optimize speech recognition by the implant
user.  At the present time there are several different types of single
and multichannel auditory prostheses being used in human subjects.
These include both monaural and binaural cochlear implants as well as
cochlear nucleus implants.  Since optimal speech processor design
depends, among other things, upon both the implanted electrode design
and the remaining auditory nervous system of the individual, it is
important in designing speech processors to do so for specific implant
designs and to test them with a representative cross section of users.
 
The NIDCD is currently supporting two different speech processor
contracts to ensure access to a sufficient number of subjects with each
of the major auditory prostheses implant designs.  Only a few of the
promising speech processing strategies have been investigated, and most
of this evaluation has been in low background noise environments.  Work
needs to be extended to permit the testing and evaluation of additional
speech processing techniques in previously implanted patients under a
range of signal-to-noise conditions.
 
This requirement represents a recompetition of work currently being
performed under contracts with Research Triangle Institute and The
University of Melbourne, Contract Nos. NO1-DC-9-2400 and NO1-DC-9-2401,
respectively.  It is expected that the incumbent contractors will
recompete.
 
The contractor will be required to come to Bethesda, Maryland, yearly to
present progress on their work at the Neural Prosthesis Workshop
sponsored by the Neural Prosthesis Program.
 
Multiple awards may be made, each with performance periods not exceeding
three years.
 
This is not a Request for Proposals.  RFP No. NIH-NIDCD-91-02 will be
issued on or about July 5, 1991, with responses due on or about
September 30, 1991.
 
To receive a copy of the RFP, please submit a written request to the
following address and supply this office with two self-addressed mailing
labels:
 
Contracting Officer
Contracts Management Branch, DEA
National Institute of Neurological Disorders and Stroke
Federal Building, Room 901
7550 Wisconsin Avenue
Bethesda, MD  20892
Attention: RFP No. NIH-NIDCD-91-02
 
All responsible sources may submit a proposal that shall be considered
by the Government.
 
$$R4 END ***************************************************************
 
$$R5 BEGIN GM-91-02 FULL-TEXT ******************************************
 
STRUCTURAL BIOLOGY AS APPLIED TO THE PROBLEM OF TARGETED DRUG DESIGN,
WITH POTENTIAL APPLICABILITY TO THE TREATMENT OF AIDS
 
RFA AVAILABLE:  GM-91-02
 
P.T. 34; K.W. 0715008, 0755025, 0790015
 
National Institute of General Medical Sciences
 
Application Receipt Date:  March 18, 1992
 
PURPOSE
 
The National Institutes of Health (NIH) announces its interest in
receiving applications to apply modern techniques of molecular structure
determination and analysis for the purpose of developing new approaches
to drug design, with potential applicability to the treatment of HIV
infection and AIDS.  However, innovative approaches to the problem of
drug design using other appropriate systems will be welcomed.
 
BACKGROUND
 
In 1987, the National Institutes of General Medical Sciences (NIGMS)
initiated a program to support groups interested in developing the area
of structure-based drug design with specific emphasis on the use of
AIDS-related systems.  The structures of several proteins, such as the
HIV protease, RNaseH, and the CD4 receptor have now been determined, and
more will soon become available.  Using these structures, and supported
by both the NIGMS and other funding programs, efforts are now under way
in many laboratories to design drugs effective in the treatment of HIV
infection and AIDS.  At NIH, structural biology studies are primarily
supported by NIGMS; drug design utilizing protein structural information
is supported by both the NIGMS and National Institute of Allergy and
Infectious Diseases.
 
Notwithstanding the advances that have been made, the number of proteins
with structures determined to high resolution is quite small and the
limiting step in the process of drug design remains the lack of
generalizable, efficient, and reproducible approaches for the use of
macromolecular structures.  Consequently, we would like to encourage
applications from any research groups with an interest in developing the
concepts and methodologies of structure-based drug design.  The intent
of this program remains the development of drugs for the treatment of
HIV infection and AIDS.  However, because basic research on targeted
drug design will be broadly applicable and information gained will be
relevant to the design of AIDS drugs, any macromolecular targets that
will facilitate the development of these approaches will be acceptable.
 
Broadly, the research goals are to stimulate the organization of
multidisciplinary groups centered around studies related to structural
biology in order to develop approaches to targeted drug design.  The
central disciplines are those such as, for example, X-ray
crystallography, NMR, and theoretical chemistry as related to molecular
modelling.  To be effective, these must be aided and, to some degree,
guided by modern research in molecular biology and pharmacology.
 
MECHANISM OF SUPPORT
 
The mechanism of support will be the program project grant (PO1).  It is
expected that three or more investigators, all pursuing independent but
interrelated projects, will be involved.  One scientist must be
designated by the applicant institution as Principal Investigator and
must bear the responsibility for the scientific and fiscal management of
the program project grant.  Most of the collaborating scientists should
be independent investigators.  For example, the support of one senior
investigator and several postdoctoral and research-associate level
scientists is not appropriate as a program project application.
Equipment and other core resources necessary for the accomplishment of
the objectives of the program project grant may be requested.
 
Informal interaction and exchange of information between all groups in
the program is expected.  All awardees are expected to participate in a
yearly conference.
 
It is anticipated that six to ten applications will be funded.  This
support level is dependent on the receipt of a sufficient number of
applications of high scientific merit.  The total project period for
applications submitted in response to the RFA may not exceed five years.
The anticipated award date will be September 1, 1992.
 
To receive the complete RFA please write:
 
Marvin Cassman, Ph.D.
National Institute of General Medical Sciences
National Institutes of Health
Westwood Building, Room 922
Bethesda, MD  20892
Telephone:  (301) 496-0186
 
For fiscal and administrative matters, contact:
 
Ms. Ann Calure
Supervisory Grants Management Specialist
Westwood building, Room 953
National Institute of General Medical Sciences
National Institutes of Health
Bethesda, MD  20892
Telephone:  (301) 496-7746
 
This program is described in the Catalog of Federal Domestic Assistance
No. 93.821.  Grants will be awarded under the authority of the Public
Health Service Act, Title III, Section 301, (Public Law 78-410, as
amended; 42 USC 241) and administered under PHS grants policies and
Federal Regulations at 42 CFR Part 52 and 45 CFR Part 74.  This program
is not subject to the intergovernmental review requirements of Executive
Order 12372 or Health Systems Agency review.
 
$$R5 END ***************************************************************
 
                        ONGOING PROGRAM ANNOUNCEMENTS
 
$$P1 BEGIN PA-91-73 ****************************************************
 
DRUG ABUSE PREVENTION RESEARCH GRANT ANNOUNCEMENT
 
PA:  PA-91-73
 
P.T. 34; K.W. 0404009, 0745027, 0755030, 0411005
 
National Institute on Drug Abuse
 
PURPOSE
 
At the National Institute on Drug Abuse (NIDA), prevention research
includes:  (1) etiologic research that seeks to identify those biologic,
genetic, psychosocial, and environmental factors that may place
individuals, families, or communities at risk for, or that may buffer or
protect against, drug use onset, progression to dependency, and the
consequences of drug abuse; and (2) preventive intervention research
that seeks to develop and test theory-based prevention strategies to
prevent the onset and progression of drug use and abuse.
 
RESEARCH OBJECTIVES
 
The primary objectives of the NIDA etiologic research program are to:
identify the common etiologic pathways to drug abuse and the critical
factors involved; determine the factors that may predispose or protect
an individual from initiation, escalation, and maintenance of drug
abuse; and develop and test theories and models of etiologies of drug
abuse.
 
The primary objective of drug abuse preventive intervention research is
to apply our scientific understanding of the causes of drug use onset
and progression to the design, development, and testing of theory-based
prevention interventions focused upon the individual, family, peer
group, and community (school, workplace, and neighborhood).
 
MECHANISM OF SUPPORT
 
Support mechanisms include:  Research Projects (RO1) and First
Independent Research Support and Transition (FIRST) Awards (R29).  These
support mechanisms represent those currently authorized and are subject
to revision and reannouncement as the advances in a particular science
dictate new and unique ways for advancing our knowledge base.  Most
investigator-initiated research is supported by research grants (RO1).
Research grants are awarded to institutions on behalf of Principal
Investigators who have designed and will direct a specific project or
set of projects.  For details on a particular support mechanism or
program, please contact the program staff listed at the end of this
announcement.
 
ELIGIBILITY
 
Applications may be submitted by public or private, nonprofit or
profit-making, organizations such as universities, colleges, hospitals,
laboratories, units of State or local governments, and eligible agencies
of the Federal government.  Women and minority investigators are
encouraged to apply.
 
APPLICATION PROCEDURES
 
Applicants must use the current version of the research grant
application form PHS 398 (rev. 10/88).  The number and title of this
announcement, "PA-91-73 Drug Abuse Prevention Research Announcement,"
must be typed in item number 2 of the face page of the PHS 398
application form.
 
Application kits containing the necessary forms and instructions may be
obtained from business offices or offices of sponsored research at most
universities, colleges, medical schools, and other major research
facilities.  If such a source is not available, the following office may
be contacted for the PHS 398 application kit:
 
Division of Research Grants
National Institutes of Health
Westwood Building, Room 240
5333 Westbard Avenue
Bethesda, MD  20852
Telephone:  (301) 496-7441
 
The signed original and six permanent legible copies of the completed
application must be sent to:
 
Division of Research Grants
National Institutes of Health
Westwood Building, Room 240
Bethesda, MD  20892**
 
RECEIPT AND REVIEW SCHEDULE
 
Receipt Dates      Initial        Advisory Council     Earliest
New/Renewal        Review         Review               Start Date
 
June 1/July 1*     Oct./Nov.      Jan./Feb.            April
Oct.1/Nov.1*       Feb./March     May/June             June
Feb.1/Mar.1*       May/June       Sept./Oct.           December
 
*Amended applications (new or renewal) are to be submitted on these
dates.
 
REVIEW PROCESS AND CRITERIA
 
The Division of Research Grants, NIH, serves as a central point for
receipt of applications for most discretionary PHS grant programs.
Applications received under this announcement will be assigned to an
initial review group (IRG) in accordance with established Public Health
Service Referral Guidelines.  The IRG, consisting primarily of
non-Federal scientific and technical experts, will review the
applications for scientific and technical merit.  Notification of the
review recommendations will be sent to the applicant after the initial
review.  Applications will receive a second-level review by the
appropriate National Advisory Council whose review may be based on
policy as well as scientific merit considerations.  Only applications
recommended for approval by the Council may be considered for funding.
 
Criteria for scientific/technical merit review of applications will
include the following:  significance and originality from a scientific
or technical standpoint of the goals of the proposed research; adequacy
of the research methodology proposed to carry out the study; feasibility
of the proposed research; qualifications and research experience of the
Principal Investigator and other key research personnel; availability of
adequate facilities, other resources, and collaborative arrangements
necessary for the research; appropriateness of budget estimates for the
proposed research activities; responsiveness to NIH/ADAMHA policy on the
inclusion of women and minorities in study populations; and adequacy of
provisions for the protection of human subjects.
 
SPECIAL INSTRUCTIONS TO APPLICANTS REGARDING IMPLEMENTATION OF ADAMHA
POLICIES CONCERNING INCLUSION OF WOMEN AND MINORITIES IN CLINICAL
RESEARCH STUDY POPULATIONS
 
Applications for ADAMHA grants and cooperative agreements are required
to include both women and minorities in study populations for clinical
research, unless compelling scientific or other justification for not
including either women or minorities is provided.  This requirement is
intended to ensure that research findings will be of benefit to all
persons at risk of the disease, disorder, or condition under study.  For
the purpose of these policies, clinical research involves human studies
of etiology, treatment, diagnosis, prevention, or epidemiology of
diseases, disorders or conditions, including but not limited to clinical
trials; and minorities include U.S. racial/ethnic minority populations
(specifically, American Indians or Alaskan Natives, Asian/Pacific
Islanders, Blacks, and Hispanics).
 
ADAMHA recognizes that it may not be feasible or appropriate in all
clinical research projects to include representation of the full array
of U.S. racial/ethnic minority populations.  However, applicants are
urged to assess carefully the feasibility of including the broadest
possible representation of minority groups.
 
Applications should include a description of the composition of the
proposed study population by gender and racial/ethnic group, and the
rationale for the numbers and kinds of people selected to participate.
This information should be included in the form PHS 398 in Section 2,
A-D of the Research Plan AND summarized in Section 2, E, Human Subjects.
 
Applications should incorporate in their study design gender and/or
minority representation appropriate to the scientific objectives of the
work proposed.  If representation of women or minorities in sufficient
numbers to permit assessment of differential effects is not feasible or
is not appropriate, the reasons for this must be explained and
justified.  The rationale may relate to the purpose of the research, the
health of the subjects, or other compelling circumstances (e.g., if in
the only study population available there is a disproportionate
representation in terms of age distribution, risk factors,
incidence/prevalence, of one gender or minority/majority group).
 
For foreign awards, the policy on inclusion of women applies fully;
since the definition of minority differs in other countries, the
applicant must discuss the relevance of research involving foreign
population groups to the United States' populations, including
minorities.
 
If the required information is not contained within the application, the
application will be returned.  Peer reviewers will address specifically
whether the research plan in the application conforms to these policies.
If gender and/or minority representation/justification are judged to be
inadequate, reviewers will consider this as a deficiency in assigning
the priority score to the application.
 
All applications/proposals for clinical research submitted to ADAMHA are
required to address these policies.  ADAMHA funding components will not
award grants that do not comply with these policies.
 
AWARD CRITERIA
 
Applications recommended for approval by the appropriate National
Advisory Council will be considered for funding on the basis of overall
scientific and technical merit of the research as determined by peer
review, Institute program needs, and availability of funds.
 
INQUIRIES
 
Further information and consultation on program requirements relevant to
prevention research can be obtained from:
 
Dr. Zili Amsel
Acting Director, Division of Epidemiology and Prevention Research
 
Additional, research program information can be obtained from:
 
Dr. Meyer Glantz
Acting Chief, Epidemiology Research Branch
 
and
 
Dr. William Bukoski
Acting Chief, Prevention Research Branch
National Institute on Drug Abuse
5600 Fishers Lane
Rockwall II, Suite 615
Rockville, MD  20857
Telephone:  (301) 443-1514
 
For administrative and fiscal matters, contact:
 
Ms. Shirley McKenney
Chief, GMB
National Institute on Drug Abuse
Parklawn Building, Room 8A-52
Rockville, MD  20857
Telephone:  (301) 443-6710
 
This program is described in the Catalog of Federal Domestic Assistance
No. 93.279.  Grants will be awarded under the authority of section 310
and 515 of the Public Health Service Act, as amended (42 USC 241 and 290
cc) and administered in accordance with the PHS Grants Policy Statement
and Federal regulations at 42 CFR Part 52 and 45 CFR Part 74.  This
program is not subject to the intergovernmental review requirements of
Executive Order 12372 or Health Systems Agency review.
 
$$P1 END ***************************************************************
 
$$P2 BEGIN PA-91-74 ****************************************************
 
RESEARCH ON DISABILITIES AND REHABILITATION SERVICES FOR PERSONS WITH
SEVERE MENTAL DISORDERS
 
PA:  PA-91-74
 
P.T. 34; K.W. 0715129, 0415001, 0730050
 
National Institute of Mental Health
 
The National Institute of Mental Health (NIMH) invites applications that
use any of the available research grant mechanisms for studies relevant
to research on disabilities resulting from severe mental disorders as
well as on rehabilitation services for persons with severe mental
disorders.  This announcement implements the research agenda recommended
in "Caring for People with Severe Mental Disorders:  A National Plan of
Research to Improve Services (NIMH National Plan)."
 
Applications may be submitted by any public or private, nonprofit or
for-profit organizations such as universities, colleges hospitals,
laboratories, units of State or local governments, and eligible agencies
of the Federal Government.  Women and minority investigators are
encouraged to apply.
 
Applications for this grant are encouraged to include both women and
minorities in study populations, unless scientific evidence or other
justification for not including them is provided.  This requirement is
intended to ensure that the research findings will be of benefit to all
persons at risk of the disease, disorder, or condition under study.  For
the purpose of these policies, clinical research involves human studies
of etiology, treatment, diagnosis, prevention, or epidemiology of
diseases, disorders, or conditions, including, but not limited to,
clinical trials; and minorities include U.S. racial/ethnic minority
populations (specifically American Indians or Alaskan Natives,
Asian/Pacific Islanders, Blacks, and Hispanics).
 
ADAMHA recognizes that it may not be feasible or appropriate in all
clinical research projects to include representation of the full array
of U.S. racial/ethnic minority populations.  However, applicants are
urged to assess carefully the feasibility of including the broadest
possible representation of minority groups.
 
Applications should include a description of the composition of the
proposed study population by gender and racial/ethnic group, and the
rationale for the numbers and kinds of people selected to participate.
This information should be included in the form PHS 398, Section 2, A-D
of the Research Plan and summarized in Section 2, E, Human Subjects.
 
Applications should incorporate in their study design gender and/or
minority representation appropriate to the scientific objectives of the
work proposed.  If representation of women or minorities in sufficient
numbers to permit assessment of differential effects is not feasible or
appropriate, the reasons for this must be explained and justified.  The
rationale may relate to the purpose of the research, the health of the
subjects, or other compelling circumstances (e.g., if in the only
subject population available there is a disproportionate representation
in terms of age distribution, risk factors, incidence/prevalence, etc.,
of one gender or minority/majority group).
 
If the required information is not contained within the application, the
review will be deferred until it is complete.  Peer reviewers will
address specifically whether the research plan in the application
conforms to these policies.  If gender and/or minority
representation/justification are judged to be inadequate, the reviewers
will consider this as a deficiency in assigning the priority score to
the application.
 
All applications/proposals for clinical research submitted to
ADAMHA/NIMH are required to address these policies.  ADAMHA/NIMH funding
components will not award grants that do not comply with these policies.
 
Applicants should also be aware that the Department of Health and Human
Services has regulations for the protection of human subjects and has
developed additional regulations for the protection of children.  A copy
of these regulations, 45 CFR 46, Protection of Human Subjects, is
available from the Office for Protection from Research Risks, National
Institutes of Health, Building 31, Room 5B59, Bethesda, Maryland 20892.
 
Applications will be received under the usual PHS receipt and review
schedule.  Applications will be reviewed by an initial review group
(IRG) consisting primarily of non-Federal scientific and technical
experts.  Applications will receive a second-level review by the
appropriate Advisory Council based on policy considerations as well as
scientific merit.  Only applications recommended for approval by Council
may be considered for funding.
 
All research applicants must use the current version of the grant
application form PHS 398 (rev. 10/88).  Support may be requested for a
period of up to five years.  Annual awards will be made subject to
continued availability of funds and progress achieved.  A competing
supplemental application may be submitted during an approved period of
support to expand the scope or protocol of a project during the approved
period.  A competing continuation (i.e., renewal) application may be
submitted before the end of an approved period of support to continue a
project.
 
Grant funds may be used for expenses clearly related and necessary to
conduct research projects, including direct costs that can be
specifically identified with the project and allowable indirect costs of
the institution.  Funds may not be used to establish, add a component
to, or operate a treatment, rehabilitation, or prevention intervention
service program.  Support for research-related treatment,
rehabilitation, or prevention services and programs may be requested
only for costs required by the research.  These costs must be justified
in terms of research objectives, methods, and designs that promise to
yield generalizable knowledge and/or make significant contributions to
theoretical concepts.
 
In fiscal year 1990, the Services Research Branch of the NIMH Division
of Applied and Services Research funded approximately $1,500,000 in
rehabilitation services and disability research.  During fiscal year
1990, the NIMH Division of Clinical Research funded approximately
$1,000,000 in disability and rehabilitation research.  However, the
amount of funding will depend on appropriated funds and program
priorities at the time of the award.
 
Copies of this full announcement and additional information may be
obtained by contacting:
 
Cille Kennedy, Ph.D., or Charles Windle, Ph.D.
Services Research Branch
Division of Applied and Services Research
Parklawn Building, Room 18C-14
Telephone:  (301) 443-1330 (Dr. Kennedy)
            (301) 443-4233 (Dr. Windle)
 
H. Alice Lowery
Division of Clinical Research
Parklawn Building, Room 10C-06
Telephone:  (301) 443-3524
 
For further information on grants management issues, applicants should
contact:
 
Stephen J. Hudak
Chief, Grants Management Section
Parklawn Building, Room 7C-23
Telephone:  (301) 443-4596
 
The mailing address for the above NIMH staff is:
 
National Institute of Mental Health
5600 Fishers Lane
Rockville, MD  20857
 
Under authority of Section 301 of the Public Health Service Act (42
U.S.C. 241), and Catalog of Federal Domestic Assistance 93.242.
 
$$P2 END ***************************************************************
 
                                    ERRATA
 
$$E1 BEGIN R3 19910503 APPEND AI-91-07 BOTH ****************************
 
ADULT AIDS CLINICAL TRIALS UNITS
 
RFA:  AI-91-07
 
P.T. 34; K.W. 0715008, 0755015
 
National Institute of Allergy and Infectious Diseases
 
The Adult AIDS Clinical Trials Units (NIH Guide for Grants and
Contracts, Vol. 20, No. 18, May 3, 1991, page 3) states that only one
optional component for Other Clinical Developmental Research will be
accepted per application.  This statement is amended to read:
applicants for Part A will be eligible to apply for two component
projects in Other Clinical Developmental Research (Part C.6); however,
they must be in different disciplines (e.g., neurology and mycology).
Each application in response to Part C.6 will be limited to $100,000 in
annual direct costs for each of the projects.
 
$$E1 END ***************************************************************
 
**THE MAILING ADDRESS GIVEN FOR SENDING APPLICATIONS TO THE DIVISION OF
RESEARCH GRANTS OR CONTACTING PROGRAM STAFF IN THE WESTWOOD BUILDING IS
THE CENTRAL MAILING ADDRESS FOR THE NATIONAL INSTITUTES OF HEALTH.
APPLICANTS WHO USE EXPRESS MAIL OR A COURIER SERVICE ARE ADVISED TO
FOLLOW THE CARRIER'S REQUIREMENTS FOR SHOWING A STREET ADDRESS.  THE
ADDRESS FOR THE WESTWOOD BUILDING IS:
 
5333 Westbard Avenue
Bethesda, Maryland 20816

                  FULL TEXT OF RFAs FOR ONLINE ACCESS